Revolution Medicines Inc (NASDAQ:RVMD) released preliminary data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies.
These data were presented during the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Phase 1/1b Trial of RMC-6236 as monotherapy in patients with advanced solid tumors harboring KRASG12X mutations.
- As of the September 11, 2023 data cut-off, RMC-6236 demonstrated an acceptable safety profile that was generally well tolerated across dose levels.
- RMC-6236 demonstrated dose-dependent increases in exposure at a steady state with minimal accumulation after repeated daily oral dosing, which is compatible with once-daily dosing.
- Clinical exposures achieved at dose levels of 80 mg QD and above were comparable to those that induced tumor regressions in preclinical xenograft models.
- Three clinical case reports illustrated tumor regressions induced by RMC-6236 in patients with ovarian cancer (KRASG12V), NSCLC (KRASG12D), or PDAC (KRASG12D).
Phase 1/1b Trial of RMC-6291 as monotherapy in patients with advanced solid tumors harboring KRASG12C mutations.
- As of October 5, 2023, RMC-6291 demonstrated preliminary evidence of clinical activity and an acceptable safety profile that was generally well tolerated across dose levels.
- Of the 10 NSCLC patients previously treated with a KRASG12C(OFF) inhibitor, 50% (n=5; one unconfirmed PR) achieved a partial response (PR) as best response, with a 100% disease control rate (DCR).
- Of the 7 NSCLC patients naïve to KRASG12C(OFF) inhibitors, 43% (n=3; two unconfirmed PRs) achieved a PR, with a 100% DCR. Among the 20 CRC patients naïve to KRASG12C(OFF) inhibitors, 40 percent (n=8; 3 unconfirmed PRs) achieved a PR as best response, with an 80 percent DCR.
- The median time to response was 1.3 months and 1.4 months for NSCLC and CRC patients, respectively.
Price Action: RVMD shares are up 20.30% at $29.11 on the last check Friday.
